Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Relutrigine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Praxis Precision Pharma Advances After A Key Year Of Achievements
    Praxis Precision Pharma Advances After A Key Year Of Achievements

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216856/0/en/Praxis-Precision-Medicines-Enters-Its-Next-Chapter-Following-a-Pivotal-Year-of-Progress.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Praxis Precision Medicines To Submit NDA For Relutrigine
    Praxis Precision Medicines To Submit NDA For Relutrigine

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203828/0/en/Praxis-Precision-Medicines-Announces-Plans-to-File-an-NDA-for-Relutrigine-in-SCN2A-and-SCN8A-Developmental-and-Epileptic-Encephalopathies-in-Early-2026.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Praxis Leads in Rare Pediatric & Adult Epilepsies at AES
    Praxis Leads in Rare Pediatric & Adult Epilepsies at AES

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201478/0/en/Praxis-AES-Wrap-up-Best-in-Class-Potential-Across-Rare-Pediatric-and-Adult-Epilepsies.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Praxis Precision Medicines Reports Positive EMBOLD Study Results
    Praxis Precision Medicines Reports Positive EMBOLD Study Results

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3200330/0/en/Praxis-Precision-Medicines-Announces-Positive-Results-from-EMBOLD-Study-for-Relutrigine-in-SCN2A-and-SCN8A-Developmental-and-Epileptic-Encephalopathies.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Praxis Gets Accelerated Path for Relutrigine in SCN2A & SCN8A DEE
    Praxis Gets Accelerated Path for Relutrigine in SCN2A & SCN8A DEE

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180282/0/en/Praxis-announces-accelerated-development-path-for-relutrigine-in-SCN2A-and-SCN8A-DEE-patients-following-positive-FDA-feedback.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.